<DOC>
	<DOCNO>NCT01147107</DOCNO>
	<brief_summary>The main objective evaluate hepatic safety raltegravir compare efavirenz , combination tenofovir emtricitabine first-line HIV treatment patient HIV hepatitis C coinfection .</brief_summary>
	<brief_title>Hepatic Safety Raltegravir Versus Efavirenz HIV Therapy Patients With HIV HCV Coinfection</brief_title>
	<detailed_description>The trial recruit 80 treatment-naive HIV-infected patient chronic hepatitis C coinfection two HIV treatment center Vietnam . Patients randomize receive either raltegravir efavirenz , combination tenofovir emtricitabine , first-line HIV therapy period 72 week . The primary endpoint rate alanine aminotransferase ( ALT ) elevation 72 week study period . Secondary endpoint include rate virological suppression , CD4 count change , number AIDS event death , rate fast glucose cholesterol measure , neurocognitive function level immune activation . Patients follow monthly first 3 month every 3 month thereafter . At end trial period , patient transfer National HIV treatment program continuation HIV therapy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>HIV infect patient , age &gt; 18 year , meet Vietnam guideline begin ART ( CD4 count &lt; 350 cells/mm3 and/or WHO stage III IV disease ) Hepatitis C infection document positive HCV antibody detectable serum HCV RNA level AST ALT ≤ 2 x ULN ( ≤ 80 U/L ) Estimated creatinine clearance ≥ 60 mL/min Any prior ART Positive Hepatitis B surface antigen Clinical evidence decompensated cirrhosis ( ascites , encephalopathy , esophageal bleed ) Requirement acute therapy AIDSdefining illness within 14 day prior study entry Currently rifampicin therapy In first trimester pregnancy , intent become pregnant , breast feeding study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV/HCV co-infection</keyword>
	<keyword>Antiretroviral therapy</keyword>
</DOC>